131 related articles for article (PubMed ID: 38069472)
21. Risankizumab-rzaa: A New Therapeutic Option for the Treatment of Crohn's Disease.
Choi D; Sheridan H; Bhat S
Ann Pharmacother; 2023 May; 57(5):579-584. PubMed ID: 36214282
[TBL] [Abstract][Full Text] [Related]
22. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
Khanna R; Preiss JC; MacDonald JK; Timmer A
Cochrane Database Syst Rev; 2015 May; (5):CD007572. PubMed ID: 25942580
[TBL] [Abstract][Full Text] [Related]
23. Selective IL-23 Inhibition by Risankizumab Modulates the Molecular Profile in the Colon and Ileum of Patients With Active Crohn's Disease: Results From a Randomised Phase II Biopsy Sub-study.
Visvanathan S; Baum P; Salas A; Vinisko R; Schmid R; Grebe KM; Davis JW; Wallace K; Böcher WO; Padula SJ; Fine JS; Panés J
J Crohns Colitis; 2018 Nov; 12(10):1170-1179. PubMed ID: 30032288
[TBL] [Abstract][Full Text] [Related]
24. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis.
Singh S; Murad MH; Fumery M; Sedano R; Jairath V; Panaccione R; Sandborn WJ; Ma C
Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):1002-1014. PubMed ID: 34688373
[TBL] [Abstract][Full Text] [Related]
25. Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension Study.
Ferrante M; Feagan BG; Panés J; Baert F; Louis E; Dewit O; Kaser A; Duan WR; Pang Y; Lee WJ; Gustafson D; Liao X; Wallace K; Kalabic J; D'Haens GR
J Crohns Colitis; 2021 Dec; 15(12):2001-2010. PubMed ID: 34077509
[TBL] [Abstract][Full Text] [Related]
26. Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial.
Danese S; Vermeire S; D'Haens G; Panés J; Dignass A; Magro F; Nazar M; Le Bars M; Lahaye M; Ni L; Bravata I; Lavie F; Daperno M; Lukáš M; Armuzzi A; Löwenberg M; Gaya DR; Peyrin-Biroulet L;
Lancet Gastroenterol Hepatol; 2022 Apr; 7(4):294-306. PubMed ID: 35120656
[TBL] [Abstract][Full Text] [Related]
27. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
MacDonald JK; Nguyen TM; Khanna R; Timmer A
Cochrane Database Syst Rev; 2016 Nov; 11(11):CD007572. PubMed ID: 27885650
[TBL] [Abstract][Full Text] [Related]
28. Upadacitinib Reduces Crohn's Disease Symptoms Within the First Week of Induction Therapy.
Colombel JF; Hisamatsu T; Atreya R; Bresso F; Thin L; Panaccione R; Parra RS; Ford S; Remple VP; Lacerda AP; Anyanwu SI; Mallick M; Garrison A; Regueiro M
Clin Gastroenterol Hepatol; 2024 Mar; ():. PubMed ID: 38492903
[TBL] [Abstract][Full Text] [Related]
29. Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study.
Sandborn WJ; D'Haens GR; Reinisch W; Panés J; Chan D; Gonzalez S; Weisel K; Germinaro M; Frustaci ME; Yang Z; Adedokun OJ; Han C; Panaccione R; Hisamatsu T; Danese S; Rubin DT; Sands BE; Afzali A; Andrews JM; Feagan BG;
Gastroenterology; 2022 May; 162(6):1650-1664.e8. PubMed ID: 35134323
[TBL] [Abstract][Full Text] [Related]
30. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial.
Loftus EV; Feagan BG; Colombel JF; Rubin DT; Wu EQ; Yu AP; Pollack PF; Chao J; Mulani P
Am J Gastroenterol; 2008 Dec; 103(12):3132-41. PubMed ID: 18853973
[TBL] [Abstract][Full Text] [Related]
31. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.
Colombel JF; Sandborn WJ; Rutgeerts P; Kamm MA; Yu AP; Wu EQ; Pollack PF; Lomax KG; Chao J; Mulani PM
Am J Gastroenterol; 2009 May; 104(5):1170-9. PubMed ID: 19352339
[TBL] [Abstract][Full Text] [Related]
32. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC.
Ferrante M; Colombel JF; Sandborn WJ; Reinisch W; Mantzaris GJ; Kornbluth A; Rachmilewitz D; Lichtiger S; D'Haens GR; van der Woude CJ; Danese S; Diamond RH; Oortwijn AF; Tang KL; Miller M; Cornillie F; Rutgeerts PJ;
Gastroenterology; 2013 Nov; 145(5):978-986.e5. PubMed ID: 23954314
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial.
Danese S; Panaccione R; Feagan BG; Afzali A; Rubin DT; Sands BE; Reinisch W; Panés J; Sahoo A; Terry NA; Chan D; Han C; Frustaci ME; Yang Z; Sandborn WJ; Hisamatsu T; Andrews JM; D'Haens GR;
Lancet Gastroenterol Hepatol; 2024 Feb; 9(2):133-146. PubMed ID: 38104569
[TBL] [Abstract][Full Text] [Related]
34. Resolution of dominant patient-reported outcome at end of induction predicts clinical and endoscopic remission in Crohn's disease.
Wong ECL; Dulai PS; Marshall JK; Jairath V; Reinisch W; Narula N
Aliment Pharmacol Ther; 2022 May; 55(9):1151-1159. PubMed ID: 35166396
[TBL] [Abstract][Full Text] [Related]
35. Cannabis for the treatment of Crohn's disease.
Kafil TS; Nguyen TM; MacDonald JK; Chande N
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012853. PubMed ID: 30407616
[TBL] [Abstract][Full Text] [Related]
36. Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials.
Augustin M; Lambert J; Zema C; Thompson EHZ; Yang M; Wu EQ; Garcia-Horton V; Geng Z; Valdes JM; Joshi A; Gordon KB
JAMA Dermatol; 2020 Dec; 156(12):1344-1353. PubMed ID: 33052382
[TBL] [Abstract][Full Text] [Related]
37. Baseline Patient-reported Symptoms Less Predictive Than MM-SES-CD for Endoscopic Remission in Crohn's Disease.
Narula N; Wong ECL; Aruljothy A; Dulai PS; Colombel JF; Marshall JK; Ferrante M; Reinisch W
J Clin Gastroenterol; 2023 Oct; 57(9):913-919. PubMed ID: 36227009
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of "top-down" treatment of early Crohn's disease by double balloon enteroscopy.
Fan R; Zhong J; Wang ZT; Li SY; Zhou J; Tang YH
World J Gastroenterol; 2014 Oct; 20(39):14479-87. PubMed ID: 25339835
[TBL] [Abstract][Full Text] [Related]
39. Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn's disease.
Gordon M; Taylor K; Akobeng AK; Thomas AG
Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD010233. PubMed ID: 25081347
[TBL] [Abstract][Full Text] [Related]
40. Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONIC post hoc analysis.
Colombel JF; Reinisch W; Mantzaris GJ; Kornbluth A; Rutgeerts P; Tang KL; Oortwijn A; Bevelander GS; Cornillie FJ; Sandborn WJ
Aliment Pharmacol Ther; 2015 Apr; 41(8):734-46. PubMed ID: 25728587
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
